Amgen Inc. Files SEC Form 4 Amid Ongoing Regulatory Scrutiny

Strategic Insights -

Amgen Inc. has made a significant filing with the U.S. Securities and Exchange Commission (SEC), highlighting the company's commitment to transparency and compliance. The filing, which was posted on May 7, 2020, showcases Amgen's dedication to providing stakeholders with critical information about the company's operations and leadership. This move is part of the company's ongoing efforts to maintain high standards in its business practices and adhere to the strict regulations set forth by the SEC.

Key Takeaways:

  • Amgen Inc. has filed a Form 4 with the SEC, which is a mandatory disclosure of changes in ownership and other equity interests.
  • The filing is in compliance with Section 12 of the 1934 Securities Exchange Act, requiring directors, officers, and owners with more than 10% stake in a class of equity securities to report on their holdings.
  • The SIC code for Amgen Inc. is 2836, indicating its classification under the biological products industry.
  • The SEC filing process, including Forms 3, 4, and 5, ensures that publicly-traded companies maintain transparency in their ownership structure and trading activities.
  • Amgen Inc.'s commitment to compliance demonstrates its dedication to maintaining high standards in business practices and regulatory adherence.

Statistics:

  • The SEC filing number for Amgen Inc. is 0001127602-20-015851.
  • The company's contact information is listed as One Amgen Center Drive, Thousand Oaks, CA 91320, with a phone number of (805) 447-1000.
  • Amgen Inc. reported a SIC code of 2836 for the biological products industry.
  • The filing was made on May 7, 2020, as reported by NewsRx.

Sources:

  • Amgen Inc. SEC Filing (Document ID: 0001127602-20-015851)
  • U.S. Securities and Exchange Commission (SEC) Form 4 Information